

10/524787

BN/SB/08A/B

DT12 Rec'd PCT/PTO 16 FEB 2005

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

EISENBACH4A 2

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | Not yet assigned |
| Filing Date | February 16, 2005 |
| First Named Inventor | Lea EISENBACH |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | EISENBACH4A |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|----------|--|----------------|
| LAB | AA | BEHR, Thomas M., "Radioimmunotherapy of Small-Volume Disease of Metastatic Colorectal Cancer: Results of a Phase II Trial with the Iodine-131-Labeled Humanized Anti-Carcinoembryonic Antigen Antibody hMN-14", Cancer (2002), Vol. 94, No. 4, pp. 1373-1381 | |
| | AB | CHAMES, Patrick, "Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library", PNAS (2000) 97:14, pp. 7969-7974 | |
| | AC | FISHMAN, Prina et al., "Autoantibodies to Tyrosinase: The Bridge between Melanoma and Vitiligo", Cancer (1997), Vol. 79, No. 8, pp. 1461-1464 | |
| | AD | GOVORKO, Dimitri et al., "Single-chain antibody against the common epitope of mutant p53: isolation and intracytosolic expression in mammalian cells", Journal of Immunological Methods (2001), Vol. 258, pp. 169-181 | |
| | AE | HUANG, Sharon K.S., "Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma Patients", (1998), Vol. III, No. 4, The Journal of Investigative Dermatology, Inc., pp. 662-667 | |
| | AF | JAGER, Elke et al., "Humoral Immune Responses of Cancer Patients Against Cancer-Testis" Antigen NY-ESO-1: Correlation with Clinical Events", (1999) 84, Int. J. Cancer (Pred. Oncol.), pp. 506-510 | |
| | AG | LEV, A. et al., "Isolation and Characterization of Human Recombinant Antibodies Endowed with the Antigen-specific, Major Histocompatibility Complex-restricted Specificity of T Cells Directed toward the Widely Expressed Tumor T-cell Epitopes of the Telomerase Catalytic Subunit", (2002), Cancer Research, vol. 62, pp. 3184-3194 | |
| | AH | MOASE, E.H. et al., "Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer", (2001), Biochimica et Biophysica Acta 1510, pp. 43-55 | |
| | AI | NIETHAMMER, Andreas G. et al., "An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice", (2002), Vaccine 20, pp. 421-429 | |
| | AJ | OKAMOTO, Tetsuro et al., "Anti-Tyrosinase-Related Protein-2 Immune Response in Vitiligo patients and Melanoma Patients Receiving Active-Specific Immunotherapy", (1998), The Journal of Investigative Dermatology, Inc., pp. 1034-1039 | |
| | AK | PARKER, Kenneth C., "Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains", (1994), Journal of Immunology, pp. 163-175 | |
| | AL | REDDISH, Mark A., "Anti-MUC1 Class I Restricted CTLs in Metastatic Breast Cancer Patients Immunized with a Synthetic Muc1 Peptide", (1998), vol. 76, Int. J. Cancer, pp. 817-823 | |
| | AM | ULLENHAG, Gustav J. et al., "Induction of IgG Subclass Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant Carcinoembryonic Antigen", (2002), Cancer Research, Vol. 62, pp. 1364-1369 | |
| ✓ | AN | YIP, Yum L., "Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines", (2002), Vol. 50, Cancer Immunol Immunother, pp. 569-587 | |

Examiner
Signature

/Lynn Bristol/

Date
Considered

07/01/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete If Known

| | |
|------------------------|---------------|
| Application Number | 10/524,787 |
| Filing Date | July 28, 2003 |
| First Named Inventor | Lea EISENBACH |
| Group Art Unit | |
| Examiner Name | |
| Attorney Docket Number | EISENBACH4A |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| LAB | AO | CARMON, L et al "Novel Breast-Tumor-Associated MUC1-Derived Peptides: Characterization in Db-/- X β 2 Microglobulin (β 2m) Null Mice Transgenic for a Chimeric HLA-A2.1/D ^b - β 2 Microglobulin Single Chain" Int. J. Cancer 85 (2000) pp:391-397 | |
| | AP | CARMON, L et al "Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1D ^b - β 2m transgenic mice: J. Clin. Invest. 110 (2002) pp: 453-462 | |
| | AQ | CELIS, ESTEBAN et al "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes" Proc. Natl. Acad. Sci. Vol. 91, (March 1984) pp: 2105-2109 | |
| | AR | CONROY, R.M. et al "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration" Clin Cancer Res. 5 (1999) pp 2330-2337. | |
| | AS | DEBLANDRE, GISELE A. et al "Expression Cloning of an Interferon-inducible 17-kDa Membrane Protein Implicated in the Control of Cell Growth" The J. of Biological Chemistry Vol. 270, No. 40 (October 1995) pp:23860-23866 | |
| | AT | FIRAT, H et al "Comparative analysis of the CD8 ⁺ T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice" Int. Immunol. 14 (2002) pp:925-934 | |
| | AU | FONG, LAWRENCE, et al "Induction of Tissue-Specific Autoimmune Prostatitis with Prostatic Acid Phosphatase Immunization: Implications for Immunotherapy of Prostate Cancer" The J. of Immunology (1997) pp:3113-3117 | |
| | AV | HISAMATSU, TADAKAZU, et al "Interferon-inducible Gene Family 1-8U Expression in Colitis associated Colon Cancer and Severely Inflamed Mucosa in Ulcerative Colitis" J. Cancer Research 59 (1999) pp:5927-5931 | |
| | AW | KAWAKAMI, YUTAKA et al "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression" The J. of Immunology (1995) pp:3961-3968 | |
| | AX | LEWIN, ANDREW R. et al "Molecular Analysis of a Human interferon-inducible gene family" J. Biochem. 199 (1991) pp:417-423 | |
| | AY | MACHLENKIN, A et al "Human CTL Epitopes Prostatic Acid Phosphates-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy" Cancer Res. 65 (2005) pp: 6435-6442 | |
| ✓ | AZ | MANDELBOIM, OFER et al "Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides" Nature Medicine, Vol 1, No. 11, (November 1995) pp:1179-1183 | |

Examiner
Signature

/Lynn Bristol/

Date
Considered

07/01/2007

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | | | | | |
|-------|---|----|---|------------------------|---------------|
| Sheet | 2 | of | 2 | Application Number | 10/524,787 |
| | | | | Filing Date | July 28, 2003 |
| | | | | First Named Inventor | Lea EISENBACH |
| | | | | Group Art Unit | |
| | | | | Examiner Name | |
| | | | | Attorney Docket Number | EISENBACH4A |

| | | | |
|----|----|---|--|
| LB | BA | MOLLER, P. et al "Small ISGs Coming Forward" J. Interferon Cytokine Res. 24 (2004) pp: 1-19 | |
| | BB | MURPHY, G.P. et al "Infusion of Dendritic Cells pulsed with HLA-A2-Specific Prostate-Specific Membrane Antigen Peptides: A Phase II Prostate Cancer Vaccine Trial Involving Patients with Hormone-Refractory Metastatic Disease" Prostate 38 (1999) pp: 73-78 | |
| | BC | PASCOLO, STEVE et al "HLA-A2.1-restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β 2 Microglobulin (β 2m) HLA-A2.1 Monochain Transgenic H-2D ^b β 2m Double Knockout Mice" J. Exp. Med. Vol. 185, No. 12, (June 1997) pp: 2043-2051 | |
| | BD | TJOA, B.A. "Follow-Up Evaluation of a Phase II Prostate Cancer Vaccine Trial" The Prostate 40 (1999) pp: 125-129 | |
| | BE | XU, LINDA L. et al "PSGR, a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor, is Overexpressed in Prostate Cancer" Cancer Research 60 (December 2000) pp:6568-6572 | |
| | BF | ZHANG, LIN et al "Gene Expression Profiles in Normal and Cancer Cells" Science Vol. 276 (May 1997) pp:1268-1272 | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Lynn Bristol/ | Date Considered | 07/01/2007 |
|--------------------|----------------|-----------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.